This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.
To own ICON, you need to believe its contract research model and technology investments can offset clinical trial volatility and current accounting noise. The key near term catalyst is whether ICON can deliver on its 2026 revenue guidance of US$7.85–US$8.15 billion despite weaker 2025 earnings. The biggest risk now is that the confirmed revenue recognition issues and internal control weaknesses weigh on confidence and constrain how investors view that guidance.
Among the recent announcements, the completion of the US$750.01 million buyback, retiring 4,504,330 shares or about 5.7 percent of the company, stands out. It amplifies the impact of any recovery in earnings per share, which matters if ICON can stabilize margins after the sharp 2025 earnings decline. That capital return also sits alongside ICON’s push into AI tools and site partnerships, potentially reinforcing the longer term catalyst of improved efficiency and win rates.
Yet beneath the revenue guidance and buyback, investors should also be aware that the accounting review and control weaknesses could still...
Read the full narrative on ICON (it's free!)
ICON’s narrative projects $8.4 billion revenue and $666.8 million earnings by 2029. This requires 1.4% yearly revenue growth and about a $67 million earnings increase from $599.5 million today.
Uncover how ICON's forecasts yield a $135.07 fair value, a 11% downside to its current price.
The more pessimistic analysts were already assuming roughly flat revenue of about US$8.5 billion and 2029 earnings of around US$618 million, so this guidance and accounting overhang may lead them to reassess both margin risks and ICON’s ability to outgrow pricing pressure.
Explore 5 other fair value estimates on ICON - why the stock might be a potential multi-bagger!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com